Jm. Gwaltney et al., RANDOMIZED CONTROLLED TRIAL OF CLEMASTINE FUMARATE FOR TREATMENT OF EXPERIMENTAL RHINOVIRUS COLDS, Clinical infectious diseases, 22(4), 1996, pp. 656-662
We used a rhinovirus challenge model to test the therapeutic efficacy
of clemastine fumarate for reducing sneezing and nasal secretion in a
double-blind, randomized clinical trial. Clemastine fumarate (1.34 mg)
or placebo was administered at 8 A.M. and 8 P.M. for 4 days, beginnin
g 24 hours, 36 hours, 48 hours, and 60 hours after viral challenge. In
fected evaluable subjects who received clemastine (n = 75) had reduced
sneeze-severity scores compared with those who received placebo (n =
75) on illness days 2 (0.3 vs, 0.5; P = .003), 3 (0.4 vs. 0.8; P = .00
03), 4 (0.3 vs, 0.5; P = .025), and 5 (0.1 vs. 0.3; P = .03); sneeze c
ounts for infected evaluable subjects (vs. counts for those who receiv
ed placebo) were reduced on illness days 2 (1.5 vs. 3.1; P = .01), 3 (
1.7 vs. 5.6; P = .0001), and 5 (0.7 vs. 1.9; P = .03). Infected evalua
ble subjects who received treatment had reduced rhinorrhea scores (com
pared with those who received placebo) on illness days 2 (0.7 vs, 1.0;
P = .04) and 3 (0.6 vs, 0.9; P = .04) and had reduced nasal secretion
weights on day 3 (3.6 g vs. 6.3 g; P = .03). Over 4 days of treatment
, mean sneeze scores for infected evaluable subjects (vs. scores for t
hose who received placebo) were reduced by 50%, mean sneeze counts by
57%, mean rhinorrhea scores by 27%, and mean nasal secretion weights b
y 35%, Other cold symptoms were unaffected by treatment. Treatment wit
h clemastine was associated with an excess incidence of dry mouth (6%)
, dry nose (19%), and dry throat (17%).